The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. This year’s metric has recorded a Price increase of 161.77%. However, over the past six months, we’ve seen a weaker performance of 279.04%. The price of RNA fallen by 23.77% over the last 30 days. And in the last five days, it has fallen by -3.97%.
Avidity Biosciences Inc’s stock has seen a smooth market performance. The company’s stock achieved a 1-year high of $27.66 on 04/03/24, and the lowest price during that time was $4.82, recorded on 10/31/23.
52-week price history of RNA Stock
A stock’s 52-week price history, including the low and high prices, can offer valuable insights into its current standing and future prospects. Avidity Biosciences Inc’s current trading price is -14.35% away from its 52-week high, while its distance from the 52-week low is 390.98%. The stock’s price range over this timeframe has been between $4.82 and $27.66. The shares of the Healthcare sector company recorded a trading volume of approximately 2.59 million for the day, which was comparatively higher than the average daily volume of 1.22 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Avidity Biosciences Inc (RNA) has experienced a quarterly rise of 147.80% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.89B and boasts a workforce of 253 employees.
How Moving Averages and Trading Volume Data Work Together
Based on Barchart.com data, the company’s moving average over the 100-day period was 13.22, with a change in price of +18.27. Similarly, Avidity Biosciences Inc recorded 1,416,877 in trading volume during the last 100 days, posting a change of +337.08%.
RNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for RNA stands at 0.02. Similarly, the long-term debt-to-equity ratio is also 0.01.
RNA Stock Stochastic Average
Avidity Biosciences Inc’s raw stochastic average for the past 50 days is currently at 77.37%. This represents a surge from the raw stochastic average of the last 20 days, which was recorded at 52.85%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 79.84% and 90.37%, respectively.
